Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

BeneVir

- PMLiVE

Morphosys’ Darzalex patent challenge hits a hurdle

Genmab and J&J's myeloma drug is a blockbuster

- PMLiVE

J&J earnings top expectations, but feels the squeeze in US

Blockbuster Xarelto declines 14% due to US competition

- PMLiVE

Blow for J&J as court refuses to overturn talc verdict

Reuters and company at loggerheads over veracity of claims

- PMLiVE

J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial

The majority of patients on Tremfya achieved at least a 90% improvement from PASI score

- PMLiVE

Dutch biotech Argenx claims $1.8bn licensing deal with J&J

Deal centres around blood cancer candidate cusatuzumab

- PMLiVE

Generic threat looms to J&J’s blockbuster Zytiga in US

Impact could also be felt by Pfizer

- PMLiVE

Janssen submits esketamine in Europe for treatment resistant depression

Fast-acting drug would be first new treatment for refractory disease in 50 years

- PMLiVE

Janssen’s single tablet Symtuza gains NHS England funding 

Janssen and Gilead combination first to reach patients

- PMLiVE

J&J files ‘breakthrough’ bladder cancer drug in US

Needed as most patients don't respond to checkpoint inhibitors

- PMLiVE

Darzalex powers ahead with frontline myeloma approval in Europe

New approval makes Darzalex first antibody drug approved in first line

- PMLiVE

J&J’s Invokana aces diabetic kidney disease trial, setting up filings

It could be the first new drug in 15 years to slow kidney damage development

- PMLiVE

J&J says real-world data finds no amputation risk for Invokana

Hopes the new data will persuade regulators to ease off warnings on the franchise

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links